PROTEOGENOMICS RESEARCH INSTITUTE FOR SYSTEMS MEDICINE
LA JOLLA, California
Total Received
$25.5M
Total Awards
6
State
California
Last Updated
Sep 24, 2025
Yearly Funding Trend
$6.6M24
$18.9M25
Top 6 Awards to PROTEOGENOMICS RESEARCH INSTITUTE FOR SYSTEMS MEDICINE
Largest individual federal awards on record for this recipient, ranked by obligated amount. Data through September 24, 2025.
| Award | Awarding Agency | Program | Place | FY | Obligation |
|---|---|---|---|---|---|
ASST_NON_P01CA221775_075 PRECISION DELIVERY AND IMAGING TO ENHANCE SOLID TUMOR THERAPY - PROJECT 1 SUMMARY EXISTING ANTIBODY-BASED INTERVENTIONS FOR CANCER RELY ON PASSIVE DELIVERY OF THE CIRCULATING DRU… | Department of Health and Human Services National Institutes of Health | 93.394 CANCER DETECTION AND DIAGNOSIS RESEARCH | CA-90 | 2025 | $13,188,464 |
ASST_NON_R01CA240703_075 ENDOTHELIAL CELL-TARGETED AMATOXIN CONJUGATES FOR EFFECTIVE THERAPY OF BREAST CANCER - SUMMARY THE OVERALL OBJECTIVE OF THE PROPOSED PROJECT IS TO HARNESS A NEWLY DISCOVERED, ACTI… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | CA-90 | 2025 | $3,583,440 |
ASST_NON_R01HL169760_075 BISPECIFIC IMMUNOTHERAPEUTIC DELIVERY SYSTEM FOR LUNG DISEASES - PROJECT SUMMARY/ABSTRACT MODERN MEDICINE HAS CREATED PRECISION DRUGS BLOCKING A SINGLE THERAPEUTIC TARGET LIKE TGF… | Department of Health and Human Services National Institutes of Health | 93.837 CARDIOVASCULAR DISEASES RESEARCH | LA JOLLA, CA-50 | 2024 | $2,754,456 |
ASST_NON_R01CA215157_075 ACTIVE DELIVERY OF PLATINUM NANOIMMUNOCONJUGATES TO IMPROVE BREAST CANCER THERAPY - THE OVERALL OBJECTIVE OF THE PROPOSED RESEARCH IS TO UTILIZE A NEWLY DISCOVERED, ACTIVE TRANSEN… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | LA JOLLA, CA-50 | 2024 | $2,270,758 |
ASST_NON_R01CA237109_075 TUMOR CAVEOLAE-TARGETED SYSTEMIC THERAPY OF BREAST CANCER WITH ANTIBODY DRUG CONJUGATES - BREAST CANCER IS THE MOST COMMONLY DIAGNOSED CANCER IN WOMEN AND IS A SECOND LEADING CAUS… | Department of Health and Human Services National Institutes of Health | 93.395 CANCER TREATMENT RESEARCH | CA-90 | 2025 | $2,099,012 |
ASST_NON_R01HL175948_075 LOCALIZING THERAPEUTICS TO TARGET LUNG MYOFIBROBLASTS AND REVERSE FIBROSIS - PROJECT SUMMARY/ABSTRACT LUNG DISEASES ARE A GLOBAL PUBLIC HEALTH PROBLEM WITH SIGNIFICANT MORBIDITY,… | Department of Health and Human Services National Institutes of Health | 93.837 CARDIOVASCULAR DISEASES RESEARCH | LA JOLLA, CA-50 | 2024 | $1,587,996 |
Top 6 awards shown, ranked by obligated amount. Dates reflect performance period; last-modified dates match USAspending.gov. Complete listings include all transaction history going back to FY2024.
Funding Agencies
View All→Source: USAspending.gov · All Recipients · California